By this approach, researchers aim to block ErbB receptors, which are known key players in the initiation of several solid tumors, including HNSCC, and favor the ex vivo T-cell expansion by IL-4 [137]. This evidence concerns the gene IL4 and head and neck squamous cell carcinoma.